Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04813107
Title A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Jiangsu Yahong Meditech Co., Ltd aka Asieris
Indications

bladder urothelial carcinoma

Therapies

APL-1202 + Tislelizumab

Tislelizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.